Latest & greatest articles for acyclovir

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on acyclovir or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on acyclovir and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for acyclovir

61. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection.

A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. 6328298 1984 07 09 1984 07 09 2013 11 21 0028-4793 310 24 1984 Jun 14 The New England journal of medicine N. Engl. J. Med. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. 1551-6 Patients with frequently recurring genital herpes were enrolled in a double-blind placebo-controlled trial comparing 200-mg acyclovir capsules (...) , given five or two times daily, with placebo. Of 47 placebo recipients, 44 (94 per cent) had recurrences during the 120-day treatment period, compared with 13 (29 per cent) of 45 patients treated with acyclovir five times daily and 18 of 51 (35 per cent) treated with acyclovir twice daily (P less than 0.001 for each regimen compared with placebo). The median time to the first clinical recurrence was 18 days in placebo recipients, compared with over 120 days in both acyclovir-treated groups (P less

NEJM1984

62. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects.

Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. 6339923 1983 05 05 1983 05 05 2013 11 21 0028-4793 308 16 1983 Apr 21 The New England journal of medicine N. Engl. J. Med. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. 916-21 We performed a double-blind placebo-controlled trial of oral (...) acyclovir in the treatment of first episodes of genital herpes simplex virus infections in 48 young adults (31 women and 17 men). Subjects were randomized to receive either placebo or acyclovir (200 mg per dose) five times daily for 10 days; they were examined on at least eight visits until healed and at monthly visits thereafter. Acyclovir treatment, as compared with placebo, significantly reduced virus shedding, new lesion formation after 48 hours, and the duration of genital lesions in both men

NEJM1983

63. Acyclovir halts progression of herpes zoster in immunocompromised patients.

Acyclovir halts progression of herpes zoster in immunocompromised patients. 6343861 1983 07 08 1983 07 08 2013 11 21 0028-4793 308 24 1983 Jun 16 The New England journal of medicine N. Engl. J. Med. Acyclovir halts progression of herpes zoster in immunocompromised patients. 1448-53 We conducted a placebo-controlled, double-blind study of acyclovir therapy for acute herpes zoster in immunocompromised patients. Of the 94 patients enrolled in the study, 52 had localized skin lesions at entry (...) , and 42 had disseminated cutaneous zoster. A one-week course of intravenous acyclovir (1500 mg per square meter of body-surface area per day) halted progression of zoster in both groups, as determined by development or progression of cutaneous dissemination, development of visceral zoster, or proportion of cases deemed treatment failures. Significantly fewer patients treated with acyclovir within the first three days after the onset of exanthem had complications of zoster, as compared with patients

NEJM1983

64. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir.

Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. 6136841 1983 10 28 1983 10 28 2015 06 16 0140-6736 2 8352 1983 Sep 24 Lancet (London, England) Lancet Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. 706-8 In a double-blind controlled study, oral acyclovir was compared with placebo in 39 consecutive patients undergoing bone-marrow transplantation. Acyclovir was given at a dose of 200 mg every 6 h from 8 days before to 35 (...) . The frequencies of HSV and CMV infections were the same in both groups after the cessation of treatment. Gluckman E E Lotsberg J J Devergie A A Zhao X M XM Melo R R Gomez-Morales M M Nebout T T Mazeron M C MC Perol Y Y eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 X4HES1O11F Acyclovir AIM IM Acyclovir administration & dosage adverse effects blood Administration, Oral Adolescent Adult Bone Marrow Transplantation Child Child, Preschool Clinical Trials as Topic

Lancet1983

65. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes.

Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. 6125728 1982 10 21 1982 10 21 2015 06 16 0140-6736 2 8298 1982 Sep 11 Lancet (London, England) Lancet Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. 571-3 A double-blind, randomised trial of acyclovir versus placebo was conducted in 31 patients with initial and 85 patients with recurrent genital herpes. 17 patients with initial and 42 with recurrent disease were treated (...) with 200 mg acyclovir by mouth five times a day for 5 days, and the remaining patients received matching placebo. In patients with initial genital herpes shedding virus acyclovir significantly reduced the duration of viral shedding, itching, and pain, the time to crusting and complete healing, and new lesion formation compared with controls. In patients with recurrence disease acyclovir significantly reduced the duration of viral shedding, time to complete healing, and new lesion formation

Lancet1982

66. Acyclovir therapy for acute herpes zoster.

Acyclovir therapy for acute herpes zoster. 6123837 1982 08 26 1982 08 26 2015 06 16 0140-6736 2 8290 1982 Jul 17 Lancet (London, England) Lancet Acyclovir therapy for acute herpes zoster. 118-21 31 adults took part in a randomised, placebo-controlled, double-blind trial of intravenous acyclovir therapy (500 mg/m2 intravenously 3 times daily for 5 days) for acute herpes zoster. Acyclovir reduced pain, decreased erythema, prevented the formation of new lesions, and healed skin faster than did (...) placebo. The duration of viral shedding was also significantly shorter in acyclovir recipients (2 days versus 5 days). However, 6(35%) of 17 acyclovir recipients had recurrence of pain after the drug was discontinued, and acyclovir did not appear to affect post-herpetic neuralgia. Acyclovir therapy was associated with a transient rise in serum creatinine levels, and may have been related to nausea and vomiting. Intravenous acyclovir was effective therapy for acute herpes zoster but the ideal treatment

Lancet1982

67. A trial of topical acyclovir in genital herpes simplex virus infections.

A trial of topical acyclovir in genital herpes simplex virus infections. 6280052 1982 06 24 1982 06 24 2013 11 21 0028-4793 306 22 1982 Jun 03 The New England journal of medicine N. Engl. J. Med. A trial of topical acyclovir in genital herpes simplex virus infections. 1313-9 Seventy-seven patients with first episodes of genital herpes and 111 with recurrent episodes were enrolled in a double-blind trial comparing topical acyclovir with a placebo (polyethylene glycol ointment). Among acyclovir (...) -treated patients with first-episode primary genital herpes, the mean duration of viral shedding (4.1 days) and the time to complete crusting of lesions present at the initiation of therapy (7.1 days) were shorter than among placebo recipients (7.0 and 10.5 days, respectively) (P less than 0.05). Acyclovir-treated patients with recurrent herpes had a shorter duration of viral shedding than placebo recipients (0.95 vs. 1.90 days) (P = 0.03). Among the patients with recurrent herpes, acyclovir reduced

NEJM1982

68. Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients.

Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. 6113352 1981 08 20 1981 08 20 2015 06 16 0140-6736 1 8235 1981 Jun 27 Lancet (London, England) Lancet Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. 1389-92 11 of 24 immunocompromised patients with mucocutaneous herpes simplex virus (HSV) infections were given intravenous acyclovir in a randomised double-blind placebo-controlled study. Patients receiving (...) acyclovir experienced no major adverse effects. The median times to cessation of new lesion formation, lesion crusting, lesion healing, cessation of pain, and termination of viral shedding were shorter in the acyclovir-treated group than in the placebo group. The time-to-event probability curves for the acyclovir and placebo groups were significantly different for cessation of pain (p=0.032) and termination of viral shedding (p=0.004). The median times to termination of viral shedding were also

Lancet1981

69. Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections.

Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. 6113353 1981 08 20 1981 08 20 2015 06 16 0140-6736 1 8235 1981 Jun 27 Lancet (London, England) Lancet Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. 1392-4 Viral cultures of mucocutaneous herpes simplex lesions became negative in 5 heart-transplant patients given a 7-day course of intravenous (...) acyclovir. Relief of pain and healing of lesions paralleled the virological response. Similar clinical and virological responses were not seen in the 5 placebo-treated patients in this double-blind placebo-controlled trial. No adverse reactions attributable to acyclovir were noted. Shedding of herpes simplex viruses recurred in 3 patients after acyclovir therapy. Chou S S Gallagher J G JG Merigan T C TC eng AI-05629-18 AI NIAID NIH HHS United States Clinical Trial Journal Article Randomized Controlled

Lancet1981